AbCellera Investor Conference Presentation Deck
CORPORATE OVERVIEW
COPYRIGHT © ABCELLERA
7
HOW DID THE INDUSTRY GET HERE?
TECHNOLOGY FOR DISCOVERY
HAS BEEN NEGLECTED
First mAB
0 Billion
Muromonab-CD3 (Orthoclone OKT3)
anti-CD3 for kidney transplantation rejection treatment
Rituximab (Rituxan)
anti-CD20 for Non-Hodgkin lymphoma
Trastuzumab (Herceptin) anti-HER2 for BC
Infliximab (Remicade) anti-TNF alpha for Crohn's disease
Adalimumab (Humira)
anti-TNF alpha for RA
Bevacizumab (Avastin)
VEGF-A for CRC
Ranibizumab (Lucentis)
VEGF-A for macular degeneration
1975 1981 1986 1994 1997 1998 2002 2003 2004 2006 2007 2009 2010
Source: Development of therapeutic antibodies for the treatment of diseases
2011
Pembrolizumab (Keytruda)
anti-PD-1 for melanoma
2012 2013 2014 2015 2016 2017 2018 2019
Market Value
of therapeutic
antibodies in 2025
300 BillionView entire presentation